Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study

Oliveira, Larissa de; Camargos, Einstein Francisco; Louzada, Luciana Lilian; Machado, Flávio V.; Novaes, María Rita Carvalho Garbi

doi:10.1016/j.psychres.2020.113591

Cited by 7 publications

(6 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, the neuropsychiatric symptoms in VCI are like those observed in AD, and the treatment is similar 14,[73][74][75] . The non-pharmacological interventions include occupational therapy, cognitive stimulation, art therapy, involvement in social interaction activities, physical activity, and psychological support for PwD and caregivers.…”

Section: Treatment Of Neuropsychiatric Symptoms In Vcimentioning

confidence: 77%

Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

Caramelli

Marinho

Laks

et al. 2022

Dement. neuropsychol.

Self Cite

View full text Add to dashboard Cite

There is currently no cure for neurodegenerative or vascular dementias, but some pharmacological and non-pharmacological interventions may contribute to alleviate symptoms, slow disease progression and improve quality of life. Current treatment approaches are based on etiology, symptom profile and stage of dementia. This manuscript presents recommendations on pharmacological and non-pharmacological treatments of dementia due to Alzheimer’s disease, vascular cognitive impairment, frontotemporal dementia, Parkinson’s disease dementia, and dementia with Lewy bodies.

show abstract

Section: Treatment Of Neuropsychiatric Symptoms In Vcimentioning

confidence: 77%

Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

Caramelli

Marinho

Laks

et al. 2022

Dement. neuropsychol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, some antidepressant drugs (citalopram, escitalopram) were shown to be clinically beneficial in at least some aspects of AD patients. Very recent clinical data indicate that antidepressants (citalopram, escitalopram, sertraline, mirtazapine), especially when combined with antipsychotic drugs (quetiapine, risperidone, olanzapine, levomepromazine), significantly reduced neuropsychiatric symptoms (agitation and/or aggression) in AD patients [ 181 ]. The authors of this study are aware of a number of limitations—the patients were not randomized and treatment adherence was not controlled.…”

Section: Discussionmentioning

confidence: 99%

“…The authors of this study are aware of a number of limitations—the patients were not randomized and treatment adherence was not controlled. Furthermore, the patients were not evaluated in terms of the QTc interval or electrolytic disturbance, which may be expected with the use of antidepressants and antipsychotics [ 181 ]. No doubt, both antidepressants and antipsychotics must be used with caution in the elderly population in order to avoid serious adverse effects.…”

Section: Discussionmentioning

confidence: 99%

Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease

Miziak

Błaszczyk²,

Czuczwar

2021

Pharmaceuticals

View full text Add to dashboard Cite

Alzheimer’s disease (AD; progressive neurodegenerative disorder) is associated with cognitive and functional impairment with accompanying neuropsychiatric symptoms. The available pharmacological treatment is of a symptomatic nature and, as such, it does not modify the cause of AD. The currently used drugs to enhance cognition include an N-methyl-d-aspartate receptor antagonist (memantine) and cholinesterase inhibitors. The PUBMED, Medical Subject Heading and Clinical Trials databases were used for searching relevant data. Novel treatments are focused on already approved drugs for other conditions and also searching for innovative drugs encompassing investigational compounds. Among the approved drugs, we investigated, are intranasal insulin (and other antidiabetic drugs: liraglitude, pioglitazone and metformin), bexarotene (an anti-cancer drug and a retinoid X receptor agonist) or antidepressant drugs (citalopram, escitalopram, sertraline, mirtazapine). The latter, especially when combined with antipsychotics (for instance quetiapine or risperidone), were shown to reduce neuropsychiatric symptoms in AD patients. The former enhanced cognition. Procognitive effects may be also expected with dietary antioxidative and anti-inflammatory supplements—curcumin, myricetin, and resveratrol. Considering a close relationship between brain ischemia and AD, they may also reduce post-brain ischemia neurodegeneration. An investigational compound, CN-105 (a lipoprotein E agonist), has a very good profile in AD preclinical studies, and its clinical trial for postoperative dementia is starting soon.

show abstract

“…Tratamento de sintomas neuropsiquiátricos em CCV Em geral, os sintomas neuropsiquiátricos no CCV são semelhantes aos observados na DA, e o tratamento é semelhante 14,[73][74][75] . As intervenções não farmacológicas incluem terapia ocupacional, estimulação cognitiva, arteterapia, envolvimento em atividades de interação social, atividade física e apoio psicológico para pessoas com demência e cuidadores.…”

Section: Tratamento Do Comprometimento Cognitivo Vascularunclassified

Tratamento da demência: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

Caramelli

Marinho

Laks

et al. 2022

Dement. neuropsychol.

Self Cite

View full text Add to dashboard Cite

RESUMO Atualmente não há tratamento curativo para as demências neurodegenerativas ou para a demência vascular, mas algumas intervenções farmacológicas e não farmacológicas podem contribuir para aliviar os sintomas, retardar a progressão da doença e melhorar a qualidade de vida. As abordagens terapêuticas atuais são baseadas na etiologia, no perfil dos sintomas e no estágio da demência. Neste artigo apresentamos recomendações sobre os tratamentos farmacológicos e não farmacológicos da demência devida à doença de Alzheimer, comprometimento cognitivo vascular, demência frontotemporal, demência da doença de Parkinson e demência com corpos de Lewy.

show abstract

Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study

Cited by 7 publications

References 56 publications

Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

Treatment of dementia: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology

Some Candidate Drugs for Pharmacotherapy of Alzheimer’s Disease

Tratamento da demência: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia

Contact Info

Product

Resources

About